Login to Your Account



Takeda moves world’s only Norovirus vaccine into phase IIb trial

By Richard Smart
Staff Writer

Monday, June 27, 2016

TOKYO – Takeda Pharmaceutical Co. Ltd. said its TAK-214 vaccine, the world’s first to tackle the Norovirus, is now in phase IIb field efficacy trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription